Dr. Choo Su Pin
BMedSci, BMBS(Nottm), MRCP(UK), FAMS Dr. Choo Su Pin is a medical oncologist who specializes in gastrointestinal cancers including colorectal, upper gastrointestinal, pancreas, hepatobiliary, peritoneal, and anal cancers. She is a global key opinion leader in hepatobiliary cancers.
- Medical Oncology – Hepatobiliary, Gastrointestinal Cancers
- Gastrointestinal cancers including colorectal, upper gastrointestinal, pancreas, hepatobiliary, peritoneal, and anal cancers
Dr. Choo graduated from the University of Nottingham Medical School, UK. She has fellowships from the Royal College of Physicians, UK and the Academy of Medicine, Singapore. Trained in medical oncology at the National Cancer Centre Singapore (NCCS). In 2011, Dr. Choo obtained a SMU-Singhealth Graduate Diploma in Healthcare Management and Leadership.
Awards and publications
At NCCS, she was Deputy Head of the Division of Medical Oncology and a Senior Consultant. She was also Chief of the Gastrointestinal Cancer Department from 2012 till 2018 and co-Director of the Comprehensive Liver Cancer Clinic from 2014 till 2019. She was a driver of many initiatives and was instrumental in setting up the Experimental Cancer Therapeutics Unit (ECRU) at NCCS which focuses on drug development and early phase oncology trials. ECRU is now one of the leading phase 1 trial units in Asia. She has led many clinical trials in gastrointestinal cancers and was Deputy Head of Clinical Trials and Epidemiological Sciences department of NCCS, who is one of the largest clinical trial centres in Singapore, before she became Chair of the Clinical Trials Steering Committee. She has received more than $4 million in grant awards for her research work as principal investigator including grants from the National Medical Research Council and received numerous other grants as co-investigator. She has publications in high impact journals like Lancet, Nature Genetics, Journal of Clinical Oncology, Annals of Oncology and Cancer Discovery. Recipient of the Singhealth Gold Excellent Service Award in 2010.
She holds the positions of Adjunct Associate Professor, Singhealth Duke-NUS Oncology Academic Clinic Programme, Duke-NUS Graduate Medical School Singapore and was Adjunct Associate Professor, Department of Medicine, Yong Loo Lin Medical School, National University of Singapore where she has done both research mentorship and clinical teaching. She has organized numerous oncology conferences including the Best of ASCO in Singapore, Asia-Pacific Liver Cancer Experts Meeting and the Asia-Pacific Gastroenterology Cancer Summit. She was Local Chair of the ESMO Asia conference in Singapore and co-chaired the ESMO preceptorship in Gastrointestinal Cancers in 2017 and 2018 Dr. Choo is the current President of the Singapore Society of Oncology and is a founding member of the SSO- Cancer Immunotherapy Consortium. She is also a member of the Society for Immunotherapy of Cancer, Society of Geriatric Oncology Singapore and the European Society of Medical Oncology. She was involved in the development of the first immune-oncology drug that was approved in liver cancer by US FDA. She is a committee member of Pan-Asia Adapted ESMO Clinical Practice Guidelines for the management of patients with Hepatocellular Carcinoma and of the Asia-Pacific Liver Cancer Experts Consensus on Intermediate HCC. She is also an overseas external reviewer of the National Comprehensive Cancer Network (NCCN) guidelines for hepatobiliary cancer and gallbladder cancer and has been a regular participant in the US NCI Hepatobiliary Cancers Taskforce Workgroup which oversees all national clinical trials for hepatobiliary cancers in the USA. She is currently a member of HCC Connect.
Places of work